4Basebio AG logo

4BSB - 4Basebio AG Share Price

€2 0.0  0.0%

Last Trade - 18/09/20

Sector
Healthcare
Size
Small Cap
Market Cap £91.5m
Enterprise Value £15.4m
Revenue £-2.60m
Position in Universe 705th / 1039
Bullish
Bearish
Unlock 4BSB Revenue
Momentum
Relative Strength (%)
1m -3.69%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -6.98%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.39 0.56 1.79 7.80 1.17 1.05 0.90 1.00 +21.8%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, 4Basebio AG revenues decreased 14% to EUR508K. Net loss applicable to common stockholders excluding extraordinary items increased from EUR1.5M to EUR3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Administration expenses increase of 36% to EUR1.8M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for 4BSB
Graphical History

Revenue

4BSB Revenue Unlock 4BSB Revenue

Net Income

4BSB Net Income Unlock 4BSB Revenue

Normalised EPS

4BSB Normalised EPS Unlock 4BSB Revenue

PE Ratio Range

4BSB PE Ratio Range Unlock 4BSB Revenue

Dividend Yield Range

4BSB Dividend Yield Range Unlock 4BSB Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
4BSB EPS Forecasts Unlock 4BSB Revenue
Profile Summary

4Basebio AG, formerly Expedeon AG, is a Germany-based biotechnology company. The Company develops and markets molecular-diagnostic technologies, such as in field of deoxyribonucleic acid (DNA) amplification and sequencing. The Company's solutions are used in drug discovery research and diagnostic product development and include TruePrime whole genome amplification technology, the Lightning-Link antibody labeling technology, the CaptSure single-step antibody capture technology, the RunBlue Bis Tris gels for electrophoresis, and colloidal gold nanoparticles for point of care lateral flow assays, such as pregnancy testing, among others. In addition, the Company offers custom services, such as antibody and particle conjugation, as well as delivers bulk orders. The Company operates through subsidiaries in Germany, Spain, Australia, Singapore, the United Kingdom and the United States.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Public Since August 10, 2000
No. of Shareholders: n/a
No. of Employees: 82
Sector Healthcare
Industry Biotechnology & Medical Research
Index Xetra Prime All Share ,
Exchange XETRA
Shares in Issue 50,105,493
Free Float (0.0%)
Eligible for
ISAs
SIPPs
4BSB Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 4BSB
Upcoming Events for 4BSB
Frequently Asked Questions for 4Basebio AG
What is the 4Basebio AG share price?

As of 18/09/20, shares in 4Basebio AG are trading at €2, giving the company a market capitalisation of £91.5m. This share price information is delayed by 15 minutes.

How has the 4Basebio AG share price performed this year?

Shares in 4Basebio AG are currently trading at €2 and the price has moved by 70.21% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the 4Basebio AG price has moved by 81.18% over the past year.

What are the analyst and broker recommendations for 4Basebio AG?

Of the analysts with advisory recommendations for 4Basebio AG, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for 4Basebio AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will 4Basebio AG next release its financial results?

4Basebio AG is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the 4Basebio AG dividend yield?

4Basebio AG does not currently pay a dividend.

Does 4Basebio AG pay a dividend?

4Basebio AG does not currently pay a dividend.

When does 4Basebio AG next pay dividends?

4Basebio AG does not currently pay a dividend.

How do I buy 4Basebio AG shares?

To buy shares in 4Basebio AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of 4Basebio AG?

Shares in 4Basebio AG are currently trading at €2, giving the company a market capitalisation of £91.5m.

Where are 4Basebio AG shares listed? Where are 4Basebio AG shares listed?

Here are the trading details for 4Basebio AG:

Country of listing: Germany
Exchange: GER
Ticker Symbol: 4BSB
What kind of share is 4Basebio AG?

Based on an overall assessment of its quality, value and momentum, 4Basebio AG is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a 4Basebio AG share price forecast 2020?

Shares in 4Basebio AG are currently priced at €2. At that level they are trading at 65% discount to the analyst consensus target price of 0.00.

Analysts covering 4Basebio AG currently have a consensus Earnings Per Share (EPS) forecast of 1.23 for the next financial year.

How can I tell whether the 4Basebio AG share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 4Basebio AG. Over the past six months, the relative strength of its shares against the market has been 14.78%. At the current price of €2, shares in 4Basebio AG are trading at 10.17% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the 4Basebio AG PE Ratio?

We were not able to find PE ratio data for 4Basebio AG.

Who are the key directors of 4Basebio AG?

4Basebio AG's management team is headed by:

Pilar de la Huerta - SUB
Joseph Fernandez - CSU
Heikki Lanckriet - CEO
Timothy McCarthy - SUB
Trevor Jarman - SUB
David Roth - CFO
Peter Llewellyn-Davies - SUB
Hansjoerg Plaggemars - SUB
Who are the major shareholders of 4Basebio AG?

Here are the top five shareholders of 4Basebio AG based on the size of their shareholding:

Zours (Wilhelm Konrad Thomas) Individual Investor
Percentage owned: 25.43% (12.7m shares)
Fernandez Family Trust Corporation
Percentage owned: 5.37% (2.69m shares)
De Busschere (Franciscus) Individual Investor
Percentage owned: 3.68% (1.84m shares)
Lanckriet (Heikki) Individual Investor
Percentage owned: 3.34% (1.67m shares)
Aramea Asset Management AG Investment Advisor/Hedge Fund
Percentage owned: 1.72% (860k shares)
Similar to 4BSB
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.